Cargando…
Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab
The patient was an 80-year-old woman with combined pulmonary fibrosis and emphysema. She was diagnosed with pulmonary pleomorphic carcinoma in the right upper lobe, which relapsed 18 months after the operation. Computed tomography showed a mass in contact with the posterior wall of the lower part of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403576/ https://www.ncbi.nlm.nih.gov/pubmed/34485050 http://dx.doi.org/10.1016/j.rmcr.2021.101501 |
_version_ | 1783746028332122112 |
---|---|
author | Kojima, Yuichi Takeyabu, Kimihiro Kimura, Mizuki Matunaga, Akihiro Kudou, Jyunya Ohata, Yoshihiro Satoh, Miki Tobioka, Hirotoshi Ishikawa, Keidai Kawamura, Takeshi |
author_facet | Kojima, Yuichi Takeyabu, Kimihiro Kimura, Mizuki Matunaga, Akihiro Kudou, Jyunya Ohata, Yoshihiro Satoh, Miki Tobioka, Hirotoshi Ishikawa, Keidai Kawamura, Takeshi |
author_sort | Kojima, Yuichi |
collection | PubMed |
description | The patient was an 80-year-old woman with combined pulmonary fibrosis and emphysema. She was diagnosed with pulmonary pleomorphic carcinoma in the right upper lobe, which relapsed 18 months after the operation. Computed tomography showed a mass in contact with the posterior wall of the lower part of the stomach. The patient was treated with two cycles of pembrolizumab, but the disease progressed. She was treated with S-1 as second-line therapy, resulting in tumor-shrinking after two cycles. Progression was not observed over the next twelve months. We report a rare case involving S-1 after immune checkpoint inhibitor treatment. |
format | Online Article Text |
id | pubmed-8403576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-84035762021-09-02 Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab Kojima, Yuichi Takeyabu, Kimihiro Kimura, Mizuki Matunaga, Akihiro Kudou, Jyunya Ohata, Yoshihiro Satoh, Miki Tobioka, Hirotoshi Ishikawa, Keidai Kawamura, Takeshi Respir Med Case Rep Case Report The patient was an 80-year-old woman with combined pulmonary fibrosis and emphysema. She was diagnosed with pulmonary pleomorphic carcinoma in the right upper lobe, which relapsed 18 months after the operation. Computed tomography showed a mass in contact with the posterior wall of the lower part of the stomach. The patient was treated with two cycles of pembrolizumab, but the disease progressed. She was treated with S-1 as second-line therapy, resulting in tumor-shrinking after two cycles. Progression was not observed over the next twelve months. We report a rare case involving S-1 after immune checkpoint inhibitor treatment. Elsevier 2021-08-26 /pmc/articles/PMC8403576/ /pubmed/34485050 http://dx.doi.org/10.1016/j.rmcr.2021.101501 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Kojima, Yuichi Takeyabu, Kimihiro Kimura, Mizuki Matunaga, Akihiro Kudou, Jyunya Ohata, Yoshihiro Satoh, Miki Tobioka, Hirotoshi Ishikawa, Keidai Kawamura, Takeshi Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab |
title | Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab |
title_full | Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab |
title_fullStr | Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab |
title_full_unstemmed | Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab |
title_short | Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab |
title_sort | case report: postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to s-1 after pembrolizumab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403576/ https://www.ncbi.nlm.nih.gov/pubmed/34485050 http://dx.doi.org/10.1016/j.rmcr.2021.101501 |
work_keys_str_mv | AT kojimayuichi casereportpostoperativeabdominalrecurrenceofpulmonarypleomorphiccarcinomashowedadramaticresponsetos1afterpembrolizumab AT takeyabukimihiro casereportpostoperativeabdominalrecurrenceofpulmonarypleomorphiccarcinomashowedadramaticresponsetos1afterpembrolizumab AT kimuramizuki casereportpostoperativeabdominalrecurrenceofpulmonarypleomorphiccarcinomashowedadramaticresponsetos1afterpembrolizumab AT matunagaakihiro casereportpostoperativeabdominalrecurrenceofpulmonarypleomorphiccarcinomashowedadramaticresponsetos1afterpembrolizumab AT kudoujyunya casereportpostoperativeabdominalrecurrenceofpulmonarypleomorphiccarcinomashowedadramaticresponsetos1afterpembrolizumab AT ohatayoshihiro casereportpostoperativeabdominalrecurrenceofpulmonarypleomorphiccarcinomashowedadramaticresponsetos1afterpembrolizumab AT satohmiki casereportpostoperativeabdominalrecurrenceofpulmonarypleomorphiccarcinomashowedadramaticresponsetos1afterpembrolizumab AT tobiokahirotoshi casereportpostoperativeabdominalrecurrenceofpulmonarypleomorphiccarcinomashowedadramaticresponsetos1afterpembrolizumab AT ishikawakeidai casereportpostoperativeabdominalrecurrenceofpulmonarypleomorphiccarcinomashowedadramaticresponsetos1afterpembrolizumab AT kawamuratakeshi casereportpostoperativeabdominalrecurrenceofpulmonarypleomorphiccarcinomashowedadramaticresponsetos1afterpembrolizumab |